Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Catalyst Pharmaceuticals Inc

CPRX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA N/A Analyst: N/A

Last Close

N/A

Market Cap N/A · Vol N/A

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

N/A

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

N/A

Momentum

Beta

N/A

vs Market

52W High

N/A

N/A below

52W Low

N/A

N/A above

Volume

N/A

Avg N/A

P/B

3.00

Price-to-book

ROE

N/A

Return on equity

Free Float

99.94%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Catalyst Pharmaceuticals Inc (CPRX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CPRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

N/A

YTD

N/A

Financials & Valuation

TTM · Annual

Total Revenue	N/A
Net Income	N/A
Revenue Growth (YoY)	+5.63%
Gross Margin	78.82%
Operating Margin	43.77%
Net Profit Margin	36.39%
ROE	N/A
ROA · ROIC	N/A · 25.49%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	0.49
P/S	5.04
P/B	3.00
P/FCF	14.24
EPS Growth	N/A
Outstanding Shares	N/A

Technical Indicators

50-Day SMA	$N/A
200-Day SMA	$N/A
RSI (14)	N/A
Beta	N/A
52-Week High	N/A
52-Week Low	N/A

Volume Today	N/A
Avg Daily Volume (30D)	N/A
Relative Volume	N/Ax
Volatility (10D)	N/A
Volatility (30D)	N/A
Free Float	99.94%

Analyst Consensus

N/A

Current Price N/A

Mean Target N/A

52W LowN/A 52W HighN/A

Current

Target

N/A N/A

Current Analyst target

· N/A analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SRHS16

ISINUS14888U1016

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.